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TopologyThe neuronal ceroid lipofuscinoses (NCLs) are a group of rare genetic diseases characterised clinically by the pro-
gressive deterioration ofmental,motor and visual functions and histopathologically by the intracellular accumu-
lation of autoﬂuorescent lipopigment – ceroid – in affected tissues. The NCLs are clinically and genetically
heterogeneous and more than 14 genetically distinct NCL subtypes have been described to date (CLN1–CLN14)
(Haltia and Goebel, 2012 [1]). In this review we will chronologically summarise work which has led over the
years to identiﬁcation of NCL genes, and outline the potential of novel genomic techniques and related bioinfor-
matic approaches for further genetic dissection and diagnosis of NCLs. This article is part of a Special Issue
entitled: The Neuronal Ceroid Lipofuscinoses or Batten Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The neuronal ceroid lipofuscinoses are a diverse group of inherited
childhood lysosomal storage disorders, now known to represent at
least 14 genetically distinct neurodegenerative diseases. The NCLs
were relatively undeﬁned until the advent of molecular genetic re-
search, in contrast to the well-stratifed disease subtypes that are
now recognised [1]. Computer-based and bioinformatic analyses
have contributed to improved understanding of the NCLs, from link-
age studies to predicting disease protein topology and mutation path-
ogenicity. This review will summarise the bioinformatic advances
that have occurred in the NCL ﬁeld over recent years, and look to-
wards future contributions.
2. The ‘90s — an era of positional cloning
The NCLs until the early 1990s were a genetically uncharacterised
grouping of clinical entities not amenable to functional or candidate
gene cloning [2]. Genetic dissection of NCLs was initially facilitated by
the discovery of polymorphic protein markers, restriction fragment
length polymorphisms (RFLPs) and the concept of disease gene
mapping through linkage analysis [3]. This approach later becameronal Ceroid Lipofuscinoses or
d Birth Defects Research Centre,
WC1N 1EH, UK. Tel.: +44 207
on).
rights reserved.more efﬁcient with discovery of multi-allelic short tandem repeat poly-
morphisms (STRPs) [4], and subsequent developments in the availabil-
ity of efﬁcient PCR-based genotyping technologies, the construction
of human genetic maps [5–7], development of computer programs
for linkage analysis [8], construction of physical maps [9], the general
evolution of positional cloning strategies [10] and most importantly
through the availability of publically accessible human DNA sequence
data from Human Genome Project [11].
This instrumental framework and the gradual build-up of impres-
sive cohorts of patients and families opened up an avenue for
deciphering the genetic and molecular basis of NCLs. The era of NCL
genetics started with identiﬁcation of linkage between juvenile NCL
or Batten disease (now CLN3) and the polymorphic protein marker
haptoglobin on chromosome 16q22 [12]. Further studies using RFLP
markers conﬁrmed linkage to chromosome 16 [13] and this was grad-
ually reﬁned, using STRP markers, leading to the genetic and physical
localization of CLN3 to chromosome 16p12 [14,15] which indicated a
major founder effect underlying the disease by demonstration of a
common haplotype of genetic markers on most of the patients'
CLN3 chromosomes [16,17]. Additional ﬁne genetic mapping [18,19]
and construction of physical maps spanning the CLN3 locus [20,21]
provided the framework for the ﬁnal identiﬁcation of CLN3 gene
encoding the ‘battenin’ protein, and delineation of the major founder
effect mutation (1 kb deletion) [22]. In parallel to these develop-
ments, four major clinical subtypes of NCL had been recognised
through clinical and genetic advances, and discovery of the CLN3
locus on chromosome 16 allowed exclusion of this region in CLN1
[23], CLN2 [15,24] and CLN5 [25].
1832 S. Kmoch et al. / Biochimica et Biophysica Acta 1832 (2013) 1831–1841CLN1was initially mapped to chromosome 1p [26]. Additional ﬁne
mapping to chromosome 1p32 [27] and construction of the CLN1
physical map [28] led to identiﬁcation of disease causing mutations
in the PPT1 gene encoding palmitoyl-protein thioesterase 1 [29].
CLN5 was initially mapped to chromosome 13q21.1–q32 [30]. The
candidate region was further narrowed using linkage disequilibrium
analysis [31] and physically localised using the ﬁber-FISH technique
[32]. The CLN5 gene was later identiﬁed using a broad spectrum of
positional cloning strategies in 1998 [33], although its function in
controlling the itinerary of lysosomal sorting receptors has been pro-
posed only recently [34]. CLN2 was initially excluded from the CLN3,
CLN1 and CLN5 loci [35] and then localised, using homozygosity map-
ping, to chromosome 11p15 [36]. Identiﬁcation of the CLN2 protein
(tripeptidyl-peptidase 1, TPP1) and its gene was achieved not by po-
sitional cloning but by biochemical methods, using comparative
proteomic analysis of mannose-6-phosphate-containing proteins
in brain extracts from patients versus controls, with subsequent
bioinformatic searching for cDNA clones encoding the N-terminal
sequence of the corresponding protein found to be absent in patients'
samples [37].
The CLN6 gene was initially excluded from the CLN3 locus on chro-
mosome 16, and from CLN5 on chromosome 13, andwas then localised,
using homozygosity mapping, to chromosome 15q [36]. Additional ﬁne
mapping together with construction of physical map and transcription
maps [38,39] and in silico cloning approach [40] led to a deﬁnition of
a set of positional candidate genes. Application of a systematic expres-
sion analysis and mutation screening ﬁnally revealed recurrent muta-
tions in an uncharacterised protein FLJ20561 [41,42], encoding an
endoplasmic reticulum membrane protein [43,44]. CLN8was originally
assigned, based on neuropathological studies, to Northern epilepsy [45],
when the gene was ﬁrst mapped to chromosome 8p [46,47]. CLN8 was
later identiﬁed by positional cloning [48], and also found to encode an
endoplasmic reticulum membrane protein [49]. Linkage analysis and
homozygosity mapping in Turkish CLN7 patients suggested that in a
subgroup of these patients the disease may be allelic to Northern epi-
lepsy [50,51].
3. The era of genomics
The ﬁnal phase in cloning of these initial NCL genes in the '00s in-
cluding CLN6 and CLN8 demonstrated the enormous potential for gene
identiﬁcation using the publically accessible data from the Human Ge-
nome Project that developed over the nineties, alongside the increased
capacity of DNA sequencing thatwas arising fromassociated technolog-
ical developments. The positional cloning approach was also greatly fa-
cilitated by other evolving resources that included gene and tissue
expression arrays [52], biological chips [53], and SNP genotyping arrays
[54]. Furthermore, there was parallel expansion in discovery of SNP
polymorphisms and establishment of the dbSNP database [55], con-
struction of SNP-based genetic maps [56], combined linkage-physical
maps [57]. In addition, methods were improved by the availability of
computer programs capable of handling tens of thousands of genotypes
for linkage analysis and haplotyping [58], and the development of inte-
grated database resources and web-based genome browsers such Map
Viewer [59], ENSEMBL [60] and the UCSC genome browser [61] that
provided an opportunity for search, retrieval and analysis of genomic
sequences and annotation data.
The discovery of CLN7 and deﬁnition of CLN9 further demonstrated
the power of these technological and conceptual advances, including
use of molecular arrays of genes and genetic markers. The CLN7 NCL
subtype was ﬁrstly found to be a genetically heterogeneous disease
subtype, since mutations in the CLN8 and CLN6 genes were identiﬁed
in subsets of patients with similar features that led to them originally
being classed together as ‘Turkish vLINCL’ [62]. Then the CLN7 gene
was mapped in families that did not carry CLN6 or CLN8 mutations,
using genome-wide genotyping with Affymetrix Human GeneChiparrays, to a ~20 Mb genomic region on chromosome 4q28.1–q28.2. Po-
sitional and functional relevant candidate genes were then screened for
mutations by genomic sequencing. This analysis revealed recurrentmu-
tations in MFSD8 encoding a lysosomal transmembrane protein [63].
The CLN9 disease subtype was excluded from other CLN forms after
negative mutation analysis of all the known CLN genes, and due to the
distinctive phenotype and gene expression proﬁle of CLN9 deﬁcient pa-
tient derived ﬁbroblasts [64].
CLN10 was identiﬁed through recognising a phenotypic similarity
between the phenotype of affected patients and that of cathepsin
D (Ctsd)-deﬁcient mice [65] and sheep [66]. Subsequent targeted
sequence analysis of the human CTSD gene in patients with non-
identiﬁed genetic causes of NCL revealed pathogenic inherited muta-
tions [67,68]. The CLN4 terminology was designated early on for
adult-onset NCL disease (Kufs) but underlying genetic heterogeneity
was evident for this disease entity, since both autosomal recessive
(formA) and autosomal dominant (form B, Parry-type)modes of inher-
itancewere found among the patients and families.What is nowknown
as the CLN4A category of disease, which is characterised by autosomal
recessive progressive myoclonus epilepsy, was identiﬁed through link-
agemapping and candidate gene sequencingwhich revealed in fact that
most of the individuals carried mutations in CLN6 [69].
4. Post-cloning bioinformatic approaches
The successful identiﬁcation of the CLN1, CLN2, CLN3, CLN5, CLN6,
CLN7, CLN8 and CLN10 genes and developments in routine DNA
sequencing dramatically changed what we understand about NCL bi-
ology over the last 2 decades, and moreover right from the beginning
greatly impacted in improving diagnostic procedures [70]. These
advances have led to identiﬁcation of more than 360 NCL-causing
mutations and have revealed both phenotypic divergence and pheno-
typic convergence of individual genetic defects [71]. Huge biological
and clinical advances have been made as a result, in dissecting corre-
lations between the underlying genotype and resulting clinical phe-
notype for the NCL forms [71].
The interpretation of genotypes is made within the context of
what is known about the encoded disease proteins' functional do-
mains and putative biological roles. Thus, signiﬁcant value has come
from bioinformatic computational studies of NCL protein tertiary to-
pology structure, derived from structure and function information.
This information has been generated from available protein domain
homologies, protein resolution structures, and comparative protein
domain evolutionary conservation data. Of the ﬁrst NCL genes to be
isolated, bioinformatics searches on the CLN1/PPT1, CLN2/TPP1 and
CLN10/Cathepsin D proteins identiﬁed them as lysosomal hydrolase
enzymes expressed as proenzymes requiring cleavage of their signal pep-
tide to mature to their enzymatic forms. All three were recognised enti-
ties prior to being connected to NCL disease, and crystal structure work
has allowed excellent understanding of the effect of NCL-associated
mutations in these proteins [72–74]. The CLN5 protein has been more
controversial since it has no recognisable domains and exists as multi-
ple protein isoforms not all of which have a deﬁned signal peptide.
However it is now widely recognised to be a soluble lysosomal glyco-
protein [75], rather than as was initially reported being a transmem-
brane protein [33].
The other novel NCL proteins CLN3, CLN6, CLN7 and CLN8 were all
identiﬁed to encode transmembrane proteins using various modelling
prediction programs such as TMHMM to predict hydrophobic trans-
membrane (TM) helices [76]. CLN3 and CLN6 have no similarity to
other known proteins and are typically modelled as simple multiple
pass proteins localised to the endosome–lysosome system vesicular
membranes or the endoplasmic reticulum membrane, respectively
(Fig. 1). To determine their toplogy they have been subject to many
complementary experimental studies using antisera and tags, and the
consensus is that CLN3 is a six TM protein with cytoplasmic N- and
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Fig. 1. Predicted structure of the CLN3, CLN6, CLN7/MFSD8 and CLN8 proteins. Missense and in-frame deletion mutations are shown, along with the protein's amino acid length.
Structures are based on TMHMM, SMART and PFAM modelling. The PFAM-predicted CLN7 MFS_1 domain is shown in brown, the CLN8 SMART-predicted TLC domain is shown
in purple. The predicted CLN3 amphipathic helix is shown as a waved line [79].
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helix [77–79]. Modelling the location of missense mutations causing
juvenile-onset CLN3 disease shows that the predicted cytosolic side of
CLN3 containing its lysosomal targeting signals [78] has fewer muta-
tions than its lumenal side where the majority reside, suggesting
functional signiﬁcance of the internal ‘face’ of the protein (Fig. 1).
CLN6 is modelled as a seven TM protein with a cytoplasmic
N-terminus and luminal C-terminus facing on different sides of theER membrane [80]. Missense mutations causing late-infantile CLN6
disease are evenly distributed across the protein, on the cytoplasmic
face containing its ER-retention domains [80], as well as on the luminal
side (Fig. 1).
CLN8 is modelled as a ﬁve TM protein which like CLN6 is an
ER-membrane protein but it is less anonymous since it contains
homology, across ~200 residues spanning TM domains 2–5, to what
is now known as the TRAM-LAG1-CLN8 domain (TLC) family of
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potentially involved in lipid-sensing, synthesis, transport or turnover
[81]. Missense mutations that cause late-infantile CLN8 disease are
distributed across the protein (Fig. 1). A number are located in the
ER luminal loop, and two are in close proximity to a C-terminal
motif (amino acids 283–286) proven in an experimental work to lo-
calise CLN8 to the ER membrane and enabling it to recycle between
the ER and ER-Golgi intermediate compartment [49]. CLN7/MFSD8
also proved to encode a protein with some better functional clues,
being a 12 TM containing member of the major facilitator superfamily
domain containing proteins, thought to be a trans-lysosomal solute
transporter. The MFS family homology is across TM domains 1–9,
and critical lysosomal targeting motifs are contained in the luminal
ninth loop, however missense mutations causing late-infantile CLN7
disease don't seem to predominate to these regions, indeed many
reside in the unique TM domains 10–12 [82,83] (Fig. 1).
5. The era of genomic sequencing
Despite the signiﬁcant advances in the era of positional cloning,
genomics and routine DNA sequencing, at least three established NCL
entities remained unexplained until 2011 — CLN4B, CLN9 and CLN11,
and apparently even more for which the underlying genetic defect
had not been identiﬁed. Further stimulus in elucidation of themolecular
basis of these remaining NCL entities was provided by the development
of novel next-generation sequencing technologies [84] and the ability to
efﬁciently capture and sequence all protein coding gene regions
(exomes) of an individual [85]. This approach, complemented by link-
age analysis, gene expression analysis and candidate gene sequencing
has revealed that CLN4B, autosomal-dominant adult-onset NCL (Parry
type), is caused by mutations in the DNAJC5 gene encoding the
cysteine-string protein alpha, CSPα [86]. This was also independently
conﬁrmed using exome sequencing in other adult-onset families
[87–89]. There was extensive pre-existing knowledge available on
the topology and function of CSPα, which is a synaptic vesicle pro-
tein that contains a DNAJ domain characteristic of Hsp40 chaper-
ones. It is attached speciﬁcally to the synaptic vesicle membrane
via a cysteine repeat domain containing hydrophobic palmitoyl
side chains (amino acids 112–137), and is thought to act via synaptic
vesicle exocytosis to play a role in synaptic transmission, and possibly
synaptic preservation [90,91]. Both mutations L115R and L116del asso-
ciated with CLN4B disease are located within this conserved cysteine
string domain and may likely interfere with membrane attachment
[86–89] (Fig. 2).
The causal gene has not yet been identiﬁed for CLN9 disease,
although the involvement of dysfunctional human Lag1 homologs or
activators has been suggested [92], however this subtype has not been
reported as subject to the exome sequencing approach yet. For the
adult-onset CLN11 disease subtype, exome sequencing revealed homo-
zygousmutations inGRN, the progranulin gene, in two siblingswithNCL
[93]. Dominant GRN mutations are a major cause of frontotemporal
lobar degeneration with TDP-43 inclusions (FTLD-TDP), the second
most common early-onset dementia [93]. FTLD-TDP has a different
presentation from CLN11 disease and is not associated with NCL-type
storage. The CLN11 progranulin protein (PGRN) is a secreted regulatory
growth factor with multiple biological roles that is involved in
neuroprotective endolysosomal processes [94]. It is modelled as
containing a signal peptide and multiple copies of the cysteine-rich
granulin motif (Fig. 2). The CLN11-associated disease causing mutation
is a frameshift early truncation mutation [93].
In the last few years, exome sequencing and targeted resequencing
have generally become efﬁcient and affordable diagnostic tools for
candidate gene identiﬁcation of many Mendelian disorders, which
does not necessarily need for its success to rely on large numbers of
patients, patients having an associated family structure, or even an a
priori diseasemodel. This approach is driven by an increased availabilityof sequencing instruments, decreased costs of targeted sequence cap-
ture and sequencing reagents, along with the steadily improving
knowledge of the genetic variability of populations that is evident
in the dbSNP database, and from exome sequencing projects [95].
This facilitates application of more effective and efﬁcient ﬁltering
approaches, additionally to the availability of programs predicting
deleterious effects of identiﬁed mutations such SIFT [96] or
PolyPhen [97] and the development of annotation and prioritization
approaches such VAAST [98,99] or VAR-MD [100], which allow for
identiﬁcation of dozen of candidate sequence variants in a single
family or even single probands.
The potential of the exome sequencing approach for adding new in-
sight into the research of NCLs has been especially highlighted by sever-
al recent gene discoveries amongst patients where the aetiology was
not ﬁrmly classed as an established NCL, andmultiple similarly affected
families were not available as used to be the requirement for gene iden-
tiﬁcation. Exome studies detected mutations in the inorganic cation
transport ATPase gene ATP13A2 in a family with atypical juvenile
NCL-associated pathology [101], and in the potassium channel gene
KCTD7 in a family with infantile-onset progressive myoclonic epilepsy
and NCL-type storage material [102]. These have been named CLN12
and CLN14 disease respectively. CLN12/ATP13A2 is a lysosomal P5-
ATPase pump of unknown substrate speciﬁcity [103], containing 10
TMdomains and anN-terminal cation ATPase domain (Fig. 2). Themis-
sense mutation causing CLN12 disease is in a large cytoplasmic loop
(Fig. 2). CLN14/KCTD7 bioinformatic modelling shows that it has a
typical Kv ion channel subunit topology [104], with a tetramerisation
domain in the N-terminus, six TM helices, and a P loop between TMdo-
main 5 and 6. The localisation of KCTD7, and the nature of its involve-
ment in neurodegeneration and lysosome biology, remains unclear.
The CLN14-associated mutations lie in highly conserved channel do-
mains, the N-terminus and second TM domain (Fig. 2). CLN13 refers
to a recessive adult-onset NCL subtype caused by mutations recently
identiﬁed by exome sequencing in the cathepsin F gene (CTSF), in fam-
ilies that previously tested negative for CLN6mutations [146]. CTSF is a
lysosomal proteolytic enzyme that was identiﬁed in the late '90s, the
substrate of which is unknown.
Interestingly, mutations in ATP13A2 are a known cause of Kufor–
Rakeb syndrome, which is an autosomal dominant disease not linked to
NCL-like storage and caused by mutations that may have a dominant-
negative-effect [105]. Moreover, KCTD7 mutations have been found
to cause progressive myoclonic epilepsy without NCL-like storage
[102]. Therefore, distinct mutations in the newest identiﬁed NCL
genes CLN11, CLN12 and CLN14 encoding progranulin, a lysosomal
ATPase and a potassium channel respectively, are connected to distinct
disease entities in each case. This illustrates the power of using themore
model-free exome sequencing-based methods to ﬁnd new NCL disease
genes, since it has led to important new clues about the underlying
aetiology, especially through new links to other disease phenotypes,
and will likely continue to do so.
6. Workﬂow for exome sequencing in identiﬁcation of NCL genes
Increased knowledge about their underlying genetic heterogeneity
has resulted in much more efﬁcient DNA diagnosis of NCLs. Custom-
designed enrichment kits for targeted re-sequencing of all the coding
or whole genomic regions of all the known CLN genes, with the prices
continuing to drop for amplicon sequencing approaches in the clinical
setting, will likely be developed and should in the near future probably
replace the currently standard of expensive gene-by-gene sequencing
based diagnostic approaches [106]. These recent NCL genetic successes
and the on-going technological advances may raise an expectation that
exome sequencing and targeted re-sequencing using speciﬁc diagnostic
panels will identify the genetic cause of the disease in all undiagnosed
NCL cases in the near future. However, it is not yet clear whether
this will be achievable. The success rate of exome sequencing in
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Fig. 2. Predicted structure of the CLN4B/CSPα, CLN11/PGRN, CLN12/ATP13A2 and CLN14/KCTD7 proteins. Missense and in-frame deletion mutations are shown, along with the
protein's amino acid length. (Therefore, no mutations are shown in GRN since only one NCL-associated mutation is known which is a frameshift trunction mutation). Structures
are based on TMHMM, SMART and PFAM modelling, and the CLN4B/CSPα DNAJ domain and resolved isolated CLN11/PGRN granulin domain crystal structures are also shown.
The CSPα cysteine string domain (green semi-circle) with its palmitoylated cysteine residues, and the DNAJ domain (blue pentagon) are shown. The progranulin (PGRN) signal
peptide is shown in red. The ATP13A2 cation ATPase domain is shown as a blue oval. The KCTD7 BTB (Broad-Complex, Tramtrack and Bric a brac) domain is shown as blue triangle.
KCTD7 mutation positions are approximate, since prediction software (PSIPred, TMHMM) do not accurately predict any TM domains. A comparison to the highly similar N-terminus
of the Shaker protein K+ channel T1 domain [145] was used as reference.
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is currently far from 100%, and may be as little as 50% as has been
reported in various clinical-research settings [107,108], and as appears
to be the case from our own experience. Diagnosis in NCL is made difﬁ-
cult by the phenotypic variability amongst patients even with muta-
tions in the same gene, and reliable diagnosis of the adult NCL forms
may not be trivial.
There are many aspects affecting the diagnostic efﬁciency of exome
sequencing, and this has to be considered by individual investigators
motivated to identify novel NCL causing genes in their patients. A ﬂow-
chart of such hypothetical project is depicted in Fig. 3. The project will
usually be initiated following detailed histopathological deﬁnition ofFamily ascertainment
Study design
Exome (genome)
sequencing
Sequence alignment
Alignment visualization
Variant detection
Variant filtering
Variant annotation
Candidate gene 
prioritization
Variant validation
Fig. 3. Exome sequencing pipeline for NCL gene identiﬁcation. See text for details.NCL and exclusion of all knownNCL genes by a combination of tradition-
al biochemical methods and/or targeted resequencing of all known NCL
genes. Detailed family ascertainment will be then performed in order to
establish the genetic model (recessive/dominant) of the disease if this is
not already clear, and to secure sufﬁcient biological materials for DNA
analysis to allow prioritization and validation of the identiﬁed candi-
date DNA variants arising from exome analysis. At this point tissue
samples for downstream functional work involving detailed clinical,
biochemical, molecular and cell biology characterisation may also be
collected.
Then, based on the genetic model of the disease, collected biological
materials and available resources, an appropriate study design must be
chosen. Optimal selection of individuals for exome sequencing is of par-
ticular importance. When resources are limited, the most genetically
distant relatives should be chosen for analysis of autosomal-dominant
NCLs. For autosomal-recessive NCLs, analysis of parents and affected sib-
lings where possible would be sought for informativeness, as well as the
analysis of trios in sporadic cases. Whenever possible, genotyping, link-
age analysis (2-point and multipoint linkage analysis, homozygosity
mapping and IBD analysis) and CNV analysis should be performed in
parallel. In cases forwhich affected tissues are available, gene expression
analysis using either RNA sequencing or standard microarrays should
always be considered. These “complementary” procedures may later
signiﬁcantly contribute to effective ﬁltering and thus increase the
diagnostic success [86,93].
Currently the preferred technological platform for exome sequenc-
ing can vary. However, it is beneﬁcial to process all samples from the
project at one time using an identical enrichment procedure and to se-
quence them in parallel on a single sequencing platform. Choosing to do
paired-end library sequencing facilitates more precise alignment and
allows better detection of indels compared to a standard single read
(fragment) library. Exome sequencing is usually outsourced to internal
core facilities, collaborating groups having access to this technology or
commercial providers. Theoretically, there is not much difference in
raw data quality between individual platforms and providers [109],
however the quality and extent of bioinformatic deliveriesmay in prac-
tice substantially differ among them. Investigators may choose to work
with original raw sequence data ﬁles, alignment ﬁles, variant call ﬁles,
annotated variant text ﬁles or highly customised reports. Effective
analysis of this type of data is usually not a one-way procedure and it
often requires multiple re-analyses along this path. In this respect, it is
important to understand the key obstacles and limits of individual
steps in exome (genome) data analysis.
The initial step in the analysis is sequence alignment, whereby each
of themillions of individual short fragment sequences (reads) generated
by sequencing is positioned according to the reference genome se-
quence to thus re-assemble the fragmented DNA sequence of the
studied sample. This represents the most computation and time
demanding part of the data analysis, with alignment facilitated by vari-
ous sequencematchingmodels incorporated in a number of either com-
mercially or publicly available short-read alignment tools [110].
Researchers have to be aware that the ﬁnal alignment outputs (i.e. the
number of aligned fragments and their positions) may signiﬁcantly dif-
fer between individual programs and parameters, thus generating dif-
ferent DNA sequence information from the studied sample. Most
alignment ﬁles are generated in SAM/BAM format [111], which can be
used for alignment visualization and inspection using several browsers
such SAMtools tview [111], Integrative Genomic Viewer [112], UCSCGe-
nome Browser [61], or several others. The same SAM/BAM format is
used for variant detection. In this process all differences between the
re-assembledDNA sequence of the studied sample and the reference ge-
nome sequence are identiﬁed and deﬁned by a genomic position and
type of the sequence change. The process of variant detection may be
also facilitated by a number of publically or commercially available
tools allowing for detection of SNPs and indels [113] as well as copy
number variants [114–116].
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tion. This process links identiﬁed variants and their genomic positions
to gene names, gene accession numbers, gene regions (e.g. exons, in-
trons, splice sites and UTRs), dbSNP ‘rs’ polymorphism identiﬁers pooled
from exome projects and other data, and the exonic function of the var-
iant (e.g. synonymous, nonsynonymous, nonsense, frameshift, stop-gain,
and stop-loss). The predicted deleterious effect for nonsynonymous
variants can also be linked in (SIFT, PolyPhen), along with information
on evolutionary conservation, plus any clinical associations, location
within known structural variants (Database of Genomic Variants) or
GWAS regions, transcription binding sites, and other regulatory regions
for example arising from the ENCODE project [117]. The most popular
and publically available annotation tools are ANNOVAR [118], SnpEff
[119], Variant tools [120] and the SeattleSeq Annotation tool (http://
snp.gs.washington.edu/SeattleSeqAnnotation/). Many other tools are ei-
ther available or being developed.
To identify and prioritise candidate variants, the ﬁnal list of all iden-
tiﬁed and annotated variantsmust be subjected to variant ﬁltering. This
is usually done based on genotypequality criteria, variant type (e.g. syn-
onymous versus nonsynonymous), the genetic model of the disease
(heterozygous versus homozygous and expected segregation in the
family), the genomic position (when linkage information is available
or homozygosity regions have been identiﬁed), the putative gene func-
tion (when biological information is available), and deleterious and
conservancy predictions. Typical criteria for the recessively inherited
NCLs in light of the ‘null’ allele effects of most NCL-related mutations,
would prioritise biallelic variants affecting exonic sequences and or
splice sites that result in a change to the protein sequence. Filtering is
also based on expected population frequency of the variant (estimated
from disease incidence), the presence of the variant in other exome se-
quencing projects performed on the same platform (platform speciﬁc
systemic errors), and the presence of the variant in population-related
databases (population speciﬁc rare variants). In addition to presence
within population-relateddatabases such as dbSNP [55], 1000Genomes
Project [121] and the NHLBI Exome Sequencing Project [122], the rela-
tive frequency must also be taken into account since it is known that
mutations causing a recessive disease can be present in a heterozygous
state in these large population databases. Variant ﬁltering for the NCLs
is thus tailored towards variants ﬁlling the criteria of having a low fre-
quency/absence from population databases. This ﬁltering procedure
may be performed easily in simple Excel ﬁle format, or alternatively ﬁl-
tering tools are available either within the abovementioned annotation
packages or elsewhere.
Filtering of annotated variants produces a list of potential can-
didate variants and this list must be subjected to candidate gene
prioritization. This may be performed either manually, evaluating bio-
logical relevance of individual variants and corresponding genes, or
the researcher may employ various tools allowing efﬁcient integrative
computational analysis of various genomic and biological data sets
and literature resources [123]. Our ability to prioritise candidate NCL
genes is limited by the current relative lack of knowledge about NCL
protein functions. There is diversity in the intracellular localization of
known NCL proteins, a lack of knowledge about their interaction part-
ners, and a variety of cellular processes (protein biosynthesis, trafﬁcking
and degradation, exocytosis, membrane turnover, etc.) which when
defective may lead to symptoms of NCL. In this respect it may be
useful to cross-compare lists of potential candidate gene variants with
gene-expression data sets and gene lists compiled from the Coordinated
Lysosomal Expression and Regulation (CLEAR) network [124,125], the
autophagy-lysosomal protein degradation pathway [126], or the lyso-
somal organization network [127]. Candidate gene variants may be
also prioritised according to their co-expression proﬁles with the
known NCL genes or genes that are linked to suggestive pathway func-
tions (eg. lysosomal, synaptic, etc). Several web-based tools such
GeneDistiller [128], Endeavour [129] or g:Proﬁler [130] may be used
for this purpose. Candidate gene prioritization may be aided by geneexpression proﬁles in relevant tissue biopsies, or even blood cells
as was the case in identiﬁcation of DNAJC5 [86]. In this respect
RNA sequencing, which allows the identiﬁcation of coding, splicing
and regulatory mutations and provides estimates of individual tran-
script amounts may be a cost-effective and efﬁcient complementary
strategy.
The most promising candidate variants must be subjected to
validation. First the particular genotype must be validated using
an independent technique such as standard Sanger capillary se-
quencing or PCR-based tests, and its segregation with the pheno-
type must be proven by genotyping the extended family. Then,
ideally additional families and cases should be tested to search
for eventual recurrence of mutations in the same candidate gene
and ﬁnally the functional signiﬁcance of deﬁned variants and genes
must be deﬁned using appropriate molecular biology, biochemistry
and cell pathology techniques.
While it is not currently envisaged that sequencing alone could
allow effective NCL diagnosis in the absence of detailed clinical
subtyping including by essential methods such as electron microscopy,
it is the case that genetic studies and the identiﬁcation of causal gene
variants can clearly greatly assist in the clinical diagnosis. However, as
stated above, the success rate of exome sequencing in undiagnosed
cases is currently as low as 50%, being inﬂuenced by the technical fac-
tors mentioned as well as the extent to which the clinical phenotyping
can help to ﬁlter variant information. When the sequence analysis fails
to identify a clear disease causing variant, a more relaxed variant ﬁlter-
ing strategy might help since it is known for example that pathogenic
mutations are present in the public polymorphism databases. The pop-
ulation origin of the NCL patientmay not suitablymatch that of samples
in publically available polymorphism databases, and therefore the
cut-off limit chosen for theminor allele frequency of any candidate var-
iant may need to be adjusted. Alternatively, different prioritization pro-
cedures could be applied, or eventually a total re-analysis of the original
raw sequence data might be necessary probably using other alignment
algorithms and variant detection tools. Another practical option if
material was available would be to sequence the gene in a panel of
ethnically-matched individuals, using Sanger sequencing; or, increas-
ingly, it may be possible to obtain pre-existing ethnically-matched fre-
quency data from available in-house exome sequences. Persisting
diagnostic failure may then shift the focus towards mutations in repet-
itive regionswhich are usually underrepresented in exome and genome
sequence data exon, for examplewithin exon 1/CpG island regions; and
to synonymous variants, deep intronic splicing mutations, noncoding
regulatory mutations; or to multiallelic models of inheritance and
other potential mutation mechanisms.7. NCL biology and other genomic bioinformatic applications
In addition to the genetic approaches described above, bioinfor-
matics has also been employed in combination with proteomic infor-
mation to identify novel causes of NCL disease. Protein analysis of NCL
brain samples was ﬁrst successfully used to identify CLN2 [37], and
more recently mass spectroscopy has identiﬁed/validated mutations
in lysosomal proteins causing storage diseases including NCLs [131].
Other approaches of a more global nature and requiring sophisticated
bioinformatic data handling have been utilised in ‘post-gene cloning’
NCL disease research, alongside experimental lab work. These col-
lectively represent the possibility of a systems level understanding
of the NCLs since they incorporate a range of genomic, proteomic,
metabolomic tools in different tissues and cell systems [132]. Such
studies include a number of efforts in gene expression proﬁling in
NCL-deﬁcient tissues and cell lines [64,133–136], complemented
by metabolomic proﬁling [137], which are beginning to reveal im-
portant information on the cellular pathways that are affected in
NCLs.
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In conclusion, genetic and genomic approaches have been suc-
cessful in unravelling the extensive heterogeneity underlying NCL
diseases, which is still not fully understood. Over the last 20 years,
gene identiﬁcation and bioinformatic efforts have increased our un-
derstanding of NCL protein biology, and the consequences of their
dysfunction in disease. Protein modelling has helped in this, and has
been instructive in correlating different classes of gene mutations
with distinct NCL forms of varying severities, and furthermore more
recently to start to connect the NCLs in a tangible way to other disease
aetiologies.
NCLs were considered in the early days of deﬁning their molecular
basis to be essentially nullizygous diseases, with many null alleles de-
scribed. However it has become clear that most NCL forms have dis-
tinct sets of mutations associated with more protracted forms – or,
now, even distinct disease entities – and therefore this simple corre-
lation no longer holds true. Indeed, a large allelic spectrum is
now apparent for NCL genes. In light of these ﬁndings, it has been
useful to examine the predicted effect on NCL protein functions of
missense/inframe-del mutations, and in Figs. 1 and 2 we focussed
on which of these are associated with classic disease forms in each
case. A summary of variants causing non-classical (protracted) disease
forms is available on the NCL Resource website, http://www.ucl.ac.uk/
ncl/mutation.shtml. A remarkable diversity in predicted mutational
consequences in NCL proteins exists, which can often be made sense
of in the context of bioinformatic modelling in terms of being causal
for a more or less profound impact on the normal protein function.
Exome sequencing andwhole-genome sequencing are changing the
view on how diagnosing and dissecting genetic heterogeneity of the
NCLs should be conducted in future; indeed, more new NCL genes
may emerge from other ﬁelds as has started to happen, for example in
exome analysis of patient cohorts with neurological disorders such as
dementia, blindness and epilepsy, that have not been examined ultra-
structurally nor yet linked to lysosome dysfunction. The NCL disease
spectrumwill likely keep being reassessed in the light of advances com-
ing from global genome techniques including exome and whole ge-
nome sequencing as they continue to improve and become ﬁnancially
tractable, alongside the many parallel efforts towards characterisation
of higher level transcriptional and translational regulation of human
genes [117,138–141]. It can be expected that these will provide, by
identiﬁcation of the full spectrumof functionally relevant variants in in-
dividual genomes, deeper insights into the biology and phenotypic
complexity of NCLs, which is a prerequisite for further progress in the
treatment and prevention of these devastating diseases. This will likely
include new information on the already suggested genetic interactions
between NCL proteins [142–144] as well as their role in functions of
other molecules and pathways, and a better appraisal of genetic modi-
fying factors that inﬂuenceNCL disease and are already known to create
different disease outcomes in patients carrying identical mutations
[71,136].
New technologies for detailed genomic and biological proﬁling of
individuals at the molecular level have been crucial in initiating a
shift towards the translation of scientiﬁc advances into healthcare.
Novel bioinformatics-related technologies applied to the NCLs in the
future would take advantage of advancing knowledge in these areas
and could include epigenetics, protein interactome networks, and
higher level gene regulation and genetic modiﬁer studies. Further de-
velopments and a multidisciplinary approach are necessary for future
more personalised medicine to become a clinical reality for patients
and families suffering from NCL diseases.
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